INTERNATIONAL CONGRESS OF
CancerGenetics
Development of cellulose-based nanocarriers for drug delivery in prostate cancer treatment
-
Fereshteh Rahdan,1 Zeinab Chaharlashkar,2 Dariush Rahdan,3 Majid Dezhman,4 Hanieh Hashemi-motahar,5 Effat Alizadeh,6,*
1. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
2. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
3. Department of Medical, Faculty of Medicine, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
4. Faculty of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran
5. Department of Molecular medicine, Faculty of advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
6. Department of Medical Biotechnology, Faculty of advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
- Introduction: Despite the important advances made in the diagnosis and treatment of prostate cancer (PC), this disease still causes the death of men in the world Prostate cancer in the advanced stages of the disease is the most lethal male malignancy. Current treatment for advanced-stage PC includes combined chemotherapy, Radiotherapy and surgery. Nevertheless, resistance to therapeutic approaches, including resistance to chemotherapy drugs, is an important challenge in the management of PC. Therefore, new therapeutic strategies based on the development of nanoscale drug delivery systems are necessary for the pharmacokinetics of chemotherapy agents, tissue absorption and improving bioavailability. For this purpose, cellulose-based nanoparticles are non-toxic, biocompatible with the human body, and biodegradable and also the inherent and unique characteristics in accepting the desired modifications such as changing the charge and adding functional groups have been considered and designed by many researchers to deliver drugs to prostate cancer cells. In a study, Ntoutoume et al. designed and synthesized cellulose-based nanocarriers through charge modification of cellulose surfaces, which optimally delivered the loaded curcumin with a low dose to the cytoplasm of prostate cancer cells. The results showed that the induction of cellular apoptosis increased. This review discusses the prospects, advances and future challenges in the delivery of chemotherapy drugs through cellulose-based nanoparticles and cellulose derivatives with the aim of their importance in the treatment of prostate cancer.
- Methods: Original articles published from 2024-2000 on cellulose-based nanocarriers in the field of anticancer drug delivery for prostate cancer treatment were searched from Elsevier and PubMed databases, Google Scholar, Scopus and Web of Science. Using these data, the properties and application of cellulose-based nanoparticles in the treatment of prostate cancer were discussed.
- Results: New nanocomplexes are synthesized with structural modifications to change the charge and create functional groups to load chemotherapeutic drugs while leaving the important intrinsic properties of cellulose intact. In this regard, the delivery platform based on cellulose nanocrystals was performed using charge modification. Cellulose nanocrystals were attracted to the positive charge of cationic cyclodextrins through electrostatic bonding, and stable complexes were designed that could load non-polar drugs into hydrophobic cavities. High release loading of hydrophobic drug in the cytoplasmic environment of prostate cancer cell was optimally reported. The results introduced cellulose nanocarrier as a suitable tool for the optimal delivery of chemotherapy drugs to cancer cells for the treatment of prostate cancer.
- Conclusion: Cellulose nanoparticles are of significant importance in overcoming drug resistance, reducing side effects and treating prostate cancer by transferring chemotherapy drugs to the target tissue.
- Keywords: Cellulose nanocarriers, Modified cellulose nanoparticles, drug delivery, prostate cancer therapy
